Malignant pleural mesothelioma in Turkey, 2000-2002

Lung Cancer

Volumn 45, Issue SUPPL., 2004, Pages

  Emri, Salih ^a   Demir, Ahmet U ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Asbestos; Erionite; Familial clustering; Higher carcinogenic potency of erionite; Proliferation index; Survival advantage

Indexed keywords

ASBESTOS; CARBOPLATIN; CISPLATIN; ERIONITE; GEMCITABINE; PACLITAXEL; PEMETREXED; UNCLASSIFIED DRUG; ZEOLITE;

ACCURACY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CAUSE OF DEATH; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CONTAMINATION; DISEASE COURSE; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; EVALUATION; GENETIC ANALYSIS; GENETIC PREDISPOSITION; HEALTH HAZARD; HUMAN; HUMAN HERPESVIRUS 8; LUNG DISEASE; MALIGNANT MESOTHELIOMA; PATHOGENESIS; PLEURA MESOTHELIOMA; PLEURECTOMY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; SIMIAN VIRUS 40; SURVIVAL RATE; SURVIVAL TIME; TURKEY (BIRD);

ASBESTOS; ENVIRONMENTAL EXPOSURE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MESOTHELIOMA; NEOPLASM STAGING; PLEURAL NEOPLASMS; PROGNOSIS; TURKEY; ZEOLITES;

EID: 3142733473     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.04.009     Document Type: Conference Paper

References (23)

1. Karakoca Y., Emri S., Cangir A.K., Baris Y.I. Environmental pleural plaques due to asbestos and fibrous zeolite exposure in Turkey. Indoor Built Environ. 6:1997;100-105
2. Dogan M., Emri S. Environmental health problems related to mineral dusts in Ankara and Eskisehir, Turkey. Yerbilimleri. 22:2000;149-161
3. Baris Y.I., Simanato l., Artvinli M., Pooley F., Saracci R., Skidmore J., et al. Epidemiological and environmental evidence of health effect of exposure to erionite fibers: a four-year study in the Cappadocian region of Turkey. Int. J. Cancer. 39:1987;10-17
4. Carthew P., Hill R.J., Edwards R.E., Lee P.N. Intrapleural administration of fibers induces mesothelioma in rats in the same relative order of hazards as occurs in man after exposure. Hum. Exp. Toxicol. 11:1992;530-534
5. Dumortier P., Çoplü L., de Maertelaer V., Emri S., Baris I., De Vuyst P. Assessment of environmental asbestos exposure in Turkey by bronchoalveolar lavage. Am. J. Respir. Crit. Care Med. 158:1998;1815-1824
6. Dumortier P., Coplu L., Broucke I., Emri S., Selcuk T., de Maertelaer V., et al. Erionite bodies and fibres in bronchoalveolar lavage fluid (BALF) of residents from Tuzköy, Cappadocia, Turkey. Occup. Environ. Med. 58:2001;261-266
7. Senyigit A., Babayigit C., Gokirmak M., Topcu F., Asan E., Coskunsel M., et al. Incidence of malignant pleural mesothelioma due to environmental asbestos fiber exposure in the Southeast of Turkey. Respiration. 67:2000;610-614
8. Baris B., Demir A.U., Shehu V., Karakoca Y., Kisacik G., Baris Y.I. Environmental fibrous (zeolite/erionite) exposure and malignant tumors other than mesothelioma. J. Environ. Path. Tox. Oncol. 15:1996;183-189
9. Metintas M., Hillerdal H., Metintas S. Malignant mesothelioma due to environmental exposure to erionite: follow up of a Turkish cohort. Eur. Respir. J. 13:1999;523-526
10. Baris YI. Lung diseases related to asbestos and fibrous zeolite exposure in Turkey. The symposium on nutrition, environment, and cancer, 31 March-3 April 2002, Ankara, Turkey.
11. Selcuk Z.T., Çöplü L., Emri S., Kalyoncu A.F., Sahin A.A., Baris Y.I. Malignant pleural mesothelioma due to environmental mineral fiber exposure in Turkey. Analysis of 135 cases. Chest. 102:1992;790-796
12. Emri S., Demir A., Dogan M., Akay H., Bozkurt B., Carbone M., et al. Lung diseases due to environmental exposures to erionite and asbestos in Turkey. Toxicol. Lett. 127(1-3):2002;251-257
13. Dogan AU. Cappadocian mesothelioma villages. The symposium on nutrition, environment, and cancer, 31 March-3 April 2002, Ankara, Turkey.
14. Roushdy-Hammady I., Siegel J., Emri S., Testa J.R., Carbone M. Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet. 357:2001;444-445
15. Carbone M., Fisher S., Powers A., Pass H.I., Rizzo P. New molecular and epidemiological issues in mesothelioma: role of SV40. J. Cell. Physiol. 180:1999;167-172
16. Emri S., Kocagoz T., Olut A., Güngen Y., Mutti L., Baris Y.I. Simian virus 40 is not a cofactor in the pathogenesis of environmentally induced malignant pleural mesothelioma in Turkey. Anticancer Res. 20:2000;891-894
17. Olut A., Ertugrul D., Kocagoz T., Er M., Emri S. HHV-8 is not a cofactor in the pathogenesis of environmentally induced malignant pleural mesothelioma. Monaldi. Arch. Chest. Dis. 55:2000;110-113
18. Ozdemir O., Emri S., Karakoca Y., Sayinalp N., Akay H., Dundar S., et al. Fibrinolytic system in plasma and pleural fluid in malignant pleural mesothelioma. Thromb. Res. 84:1996;121-128
19. Tansan S., Emri S., Selcuk T., Koc Y., Hesketh P., Heeren T., et al. Treatment of malignant pleural mesothelioma with cisplatin, mitomycin C and alpha interferon. Oncology. 51:1994;348-351
20. Emri S., Akbulut H., Zorlu F., Dincol D., Akay H., Gungen Y., et al. Prognostic significance of flow cytometric DNA analysis in patients with malignant pleural mesothelioma. Lung Cancer. 33:2001;109-114
21. Olut A., Firat P., Ertugrul D., Gungen Y., Emri S. Ras oncoprotein expression in erionite-and asbestos-induced Turkish malignant pleural mesothelioma patients-a pilot study. Resp. Med. 95:2001;697-698
22. Hughes A., Calvert P., Azzabi A., Plummer R., Johnson R., Rusthoven J., et al. Phase I clinical and pharmacokinetic study of premetrexed and carboplatin in patients with malignant pleural mesothelioma. J. Clin. Oncol. 20:2002;3533-3544
23. Scagliotti G.V., Shin D.M., Kindler H.L., Vasconcelles M.J., Keppler U., Manegold C., et al. Phase II study of premetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J. Clin. Oncol. 21:2003;1556-1561